ListarGrupo de investigación cardiovascular (GRINCAR) por tema "Anthracycline chemotherapy"
Mostrando ítems 1-2 de 2
-
Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors
(AlphaMed Press, 2015-07-16)[Abstract] INTRODUCTION: Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data from longitudinal studies of diastolic dysfunction (DD) in this group ... -
Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors
(Elsevier, 2023-04-18)[Abstract] Introduction. Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data on longitudinal studies about early and late onset cardiotoxicity in this ...